Search

In the industrialized countries and, in particular, in France, given the means of prevention, early screening and treatment of HIV infection, there is almost no evidence of opportunistic infections among immigrants and in some disadvantaged socio-professional groups. We here report the case of a 42-year old African immigrant HIV1 positive man with impaired general condition hospitalized for infectious syndrome. He had received antiretroviral therapy for 2 years and stopped it four months before admission. He had had pulmonary tuberculosis treated and declared cured in February 2017. Clinical examination showed slow ideation, a temperature of 39.6°C and weight loss. The patient had nadir CD4 cell counts 12/mm3 and HIV viral load log value 5.80. Thoracoabdominal CT scan and brain MRI showed intra-abdominal and thoracic lesions as well as brain lesions before diagnostic confirmation of tuberculosis and toxoplasmosis. The patient underwent triple antiretroviral therapy on day 15 of antituberculosis treatment. Then he underwent toxoplasmosis treatment with favorable outcome. [ABSTRACT FROM AUTHOR]

Importance: The role of herpes simplex virus (HSV) reactivation on morbidity and mortality in patients in the intensive care unit requiring mechanical ventilation remains unknown., Objective: To determine whether preemptive treatment with intravenous acyclovir reduces the duration of mechanical ventilation in patients with HSV oropharyngeal reactivation., Design, Setting, and Participants: A double-blind, placebo-controlled randomized clinical trial was conducted in 16 intensive care units in France. Participants included 239 adults (age, >18 years) who received mechanical ventilation for at least 96 hours and continued to receive mechanical ventilation for 48 hours or more, with HSV oropharyngeal reactivation. Patients were enrolled between February 2, 2014, and February 22, 2018., Interventions: Participants were randomized to receive intravenous acyclovir, 5 mg/kg, 3 times daily for 14 days or a matching placebo., Main Outcomes and Measures: The primary end point was ventilator-free days from randomization to day 60. Prespecified secondary outcomes included mortality at 60 days. Main analyses were conducted on an intention-to-treat basis., Results: Of 239 patients enrolled and randomized, 1 patient withdrew consent, leaving 238 patients, with 119 patients in both the acyclovir and placebo (control) groups (median [IQR] age, 61 [50-70] years; 76 [32%] women) available for primary outcome measurement. On day 60, the median (IQR) numbers of ventilator-free days were 35 (0-53) for acyclovir recipients and 36 (0-50]) for controls (P = .17 for between-group comparison). Among secondary outcomes, 26 patients (22%) and 39 patients (33%) had died at day 60 (risk difference, 0.11, 95% CI, -0.004 to 0.22, P = .06). The adverse event frequency was similar for both groups (28% in the acyclovir group and 23% in the placebo group, P = .40), particularly acute renal failure post randomization affecting 3 acyclovir recipients (3%) and 2 controls (2%). Four patients (3%) in the acyclovir group vs none in the placebo group stopped the study drug for treatment-related adverse events., Conclusions and Relevance: In patients receiving mechanical ventilation for 96 hours or more with HSV reactivation in the throat, use of acyclovir, 5 mg/kg, 3 times daily for 14 days, did not increase the number of ventilator-free days at day 60, compared with placebo. These findings do not appear to support routine preemptive use of acyclovir in this setting., Trial Registration: ClinicalTrials.gov identifier: NCT02152358.